Page 2 of 9 SEC Filing CUSIP No. 15130J 109 SC 13D Page 2 of 11
1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Aisling Capital II, LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) x 3 SEC USE ONLY 4 SOURCE OF FUNDS OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 1,232,278 (including 39,218 shares of the Issuer’s common stock issuable upon the exercise of preferred share purchase warrants expiring on August 5, 2018 (the “Warrants”)) 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 1,232,278 10 SHARED DISPOSITIVE POWER 0
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,232,278 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.6%(1) 14 TYPE OF REPORTING PERSON PN
(1) Based on 48,169,733 shares of the Issuer’s common stock issued and outstanding as of February 18, 2016, as reported in the Issuer’s annual report on Form 10-K filed with the Securities Exchange Commission (the “SEC”) on February 25, 2016.
Follow Melinta Therapeutics Inc. W (NASDAQ:MLNT)
Follow Melinta Therapeutics Inc. W (NASDAQ:MLNT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
| CUSIP No. 15130J 109 | SC 13D | Page 2 of 11 |
| 1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Aisling Capital II, LP | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 1,232,278 (including 39,218 shares of the Issuer’s common stock issuable upon the exercise of preferred share purchase warrants expiring on August 5, 2018 (the “Warrants”)) |
| 8 | SHARED VOTING POWER 0 | |
| 9 | SOLE DISPOSITIVE POWER 1,232,278 | |
| 10 | SHARED DISPOSITIVE POWER 0 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,232,278 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.6%(1) | |
| 14 | TYPE OF REPORTING PERSON PN |
| (1) | Based on 48,169,733 shares of the Issuer’s common stock issued and outstanding as of February 18, 2016, as reported in the Issuer’s annual report on Form 10-K filed with the Securities Exchange Commission (the “SEC”) on February 25, 2016. |
Follow Melinta Therapeutics Inc. W (NASDAQ:MLNT)
Follow Melinta Therapeutics Inc. W (NASDAQ:MLNT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
